{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:32:15Z","timestamp":1777984335997,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04837-1","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:52:50Z","timestamp":1774054370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment patterns and adverse events of antiseizure medications among adult patients with epilepsy: a single centre observational cross-sectional study in Northern Sri Lanka"],"prefix":"10.1186","volume":"26","author":[{"given":"Yalini","family":"Guruparan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajantha","family":"Keshavaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiyahiny S.","family":"Navaratinaraja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"issue":"3","key":"4837_CR1","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2468-2667(24)00302-5","volume":"10","author":"GBD Epilepsy Collaborators","year":"2025","unstructured":"GBD Epilepsy Collaborators. Global, regional, and national burden of epilepsy, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Public Health. 2025;10(3):e203\u201327. https:\/\/doi.org\/10.1016\/S2468-2667(24)00302-5.","journal-title":"Lancet Public Health"},{"key":"4837_CR2","doi-asserted-by":"publisher","first-page":"1448596","DOI":"10.3389\/fneur.2024.1448596","volume":"15","author":"LZ Yang","year":"2024","unstructured":"Yang LZ, Guo Y, Wang ZQ, et al. A population-based analysis of the global burden of epilepsy across all age groups (1990-2021): utilizing the Global Burden of Disease 2021 data. Front Neurol. 2024;15:1448596. https:\/\/doi.org\/10.3389\/fneur.2024.1448596.","journal-title":"Front Neurol"},{"issue":"4","key":"4837_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/09727531231185991","volume":"30","author":"TM Belete","year":"2023","unstructured":"Belete TM. Recent progress in the development of new antiepileptic drugs with novel targets. Ann Neurosci. 2023;30(4):262\u201376. https:\/\/doi.org\/10.1177\/09727531231185991.","journal-title":"Ann Neurosci"},{"issue":"9","key":"4837_CR4","doi-asserted-by":"publisher","first-page":"e2589","DOI":"10.1002\/brb3.2589","volume":"12","author":"P Ioannou","year":"2022","unstructured":"Ioannou P, Foster DL, Sander JW, et al. The burden of epilepsy and unmet need in people with focal seizures. Brain Behav. 2022;12(9):e2589. https:\/\/doi.org\/10.1002\/brb3.2589.","journal-title":"Brain Behav"},{"key":"4837_CR5","volume-title":"Epilepsy A public health comparative summary","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Epilepsy A public health comparative summary. Geneva: WHO; 2019.\u00a0Available at\u00a0https:\/\/www.who.int\/publications\/i\/item\/epilepsy-a-public-health-imperative. Accessed Oct 25 2025."},{"issue":"8","key":"4837_CR6","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2174\/011570159X323666241029171256","volume":"23","author":"YH Ng","year":"2025","unstructured":"Ng YH, Jamil SNH, Sarian MN, et al. Antiseizure medications: advancements, challenges, and prospects in drug development. Curr Neuropharmacol. 2025;23(8):879\u2013906. https:\/\/doi.org\/10.2174\/011570159X323666241029171256.","journal-title":"Curr Neuropharmacol"},{"issue":"s2","key":"4837_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/epi4.12268","volume":"3","author":"JM Rho","year":"2018","unstructured":"Rho JM, White HS. Brief history of anti-seizure drug development. Epilepsia Open. 2018;3(s2):114\u20139. https:\/\/doi.org\/10.1002\/epi4.12268.","journal-title":"Epilepsia Open"},{"key":"4837_CR8","doi-asserted-by":"publisher","first-page":"103558","DOI":"10.1016\/j.eclinm.2025.103558","volume":"89","author":"AYL Chan","year":"2025","unstructured":"Chan AYL, Yuen ASC, Hsia Y, et al. Antiseizure medications consumption in 73 countries and regions from 2012 to 2022: a longitudinal trend study. eClin Med. 2025;89:103558. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103558.","journal-title":"eClin Med"},{"issue":"10","key":"4837_CR9","doi-asserted-by":"publisher","first-page":"e0299964","DOI":"10.1371\/journal.pone.0299964","volume":"19","author":"B Shawel","year":"2024","unstructured":"Shawel B, Berhane Y. Adherence to anti-seizure medications and self-reported availability and affordability of the medications in Addis Ababa, Ethiopia. PLoS ONE. 2024;19(10):e0299964. https:\/\/doi.org\/10.1371\/journal.pone.0299964.","journal-title":"PLoS ONE"},{"issue":"7","key":"4837_CR10","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.4103\/jfmpc.jfmpc_405_19","volume":"8","author":"MA Elsayed","year":"2019","unstructured":"Elsayed MA, El-Sayed NM, Badi S, et al. Factors affecting adherence to antiepileptic medications among Sudanese individuals with epilepsy: a cross-sectional survey. J Fam Med Prim Care. 2019;8(7):2312\u20137. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_405_19.","journal-title":"J Fam Med Prim Care"},{"key":"4837_CR11","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.2147\/PPA.S377910","volume":"16","author":"F Bekele","year":"2022","unstructured":"Bekele F. Non-adherence to antiepileptic drugs and associated factors among epileptic patients at ambulatory clinic of southwestern Ethiopian hospital: a cross-sectional study. Patient Prefer Adher. 2022;16:1865\u201373. https:\/\/doi.org\/10.2147\/PPA.S377910.","journal-title":"Patient Prefer Adher"},{"issue":"9","key":"4837_CR12","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","volume":"35","author":"W L\u00f6scher","year":"2021","unstructured":"L\u00f6scher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35(9):935\u201363. https:\/\/doi.org\/10.1007\/s40263-021-00827-8.","journal-title":"CNS Drugs"},{"key":"4837_CR13","doi-asserted-by":"publisher","first-page":"1411134","DOI":"10.3389\/fphar.2024","volume":"15","author":"MMF Girgis","year":"2024","unstructured":"Girgis MMF, Farkasinszky G, Fekete K, et al. Seriousness and outcomes of reported adverse drug reactions in old and new antiseizure medications: a pharmacovigilance study using EudraVigilance database. Front Pharmacol. 2024;15:1411134. https:\/\/doi.org\/10.3389\/fphar.2024.","journal-title":"Front Pharmacol"},{"issue":"6","key":"4837_CR14","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","volume":"19","author":"E Perucca","year":"2020","unstructured":"Perucca E, Brodie MJ, Kwan P, et al. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19(6):544\u201356. https:\/\/doi.org\/10.1016\/S1474-4422(20)30035-1.","journal-title":"Lancet Neurol"},{"key":"4837_CR15","doi-asserted-by":"publisher","first-page":"100836","DOI":"10.1016\/j.ebr.2025.100836","volume":"32","author":"MA Morales-Morales","year":"2025","unstructured":"Morales-Morales MA, Garc\u00eda-G\u00f3mez E, San-Juan D, et al. Network analysis of antiseizure medication use, efficacy, and safety in epilepsy: A retrospective cohort study in a tertiary care center. Epilepsy Behav Rep. 2025;32:100836. https:\/\/doi.org\/10.1016\/j.ebr.2025.100836.","journal-title":"Epilepsy Behav Rep"},{"key":"4837_CR16","doi-asserted-by":"publisher","first-page":"1435075","DOI":"10.3389\/fneur.2024.1435075","volume":"15","author":"Y Naji","year":"2024","unstructured":"Naji Y, Hrouch W, Laadami S, et al. Anti-seizure medication prescription preferences: a Moroccan multicenter study. Front Neurol. 2024;15:1435075. https:\/\/doi.org\/10.3389\/fneur.2024.1435075.","journal-title":"Front Neurol"},{"issue":"8","key":"4837_CR17","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/epi.17668","volume":"64","author":"SL Fong","year":"2023","unstructured":"Fong SL, Thuy Le MA, Lim KS, et al. Affordability of newer antiseizure medications in Asian resource-limited countries. Epilepsia. 2023;64(8):2116\u201325. https:\/\/doi.org\/10.1111\/epi.17668.","journal-title":"Epilepsia"},{"issue":"1","key":"4837_CR18","doi-asserted-by":"publisher","first-page":"e000430","DOI":"10.1136\/bmjpo-2018-000430","volume":"3","author":"J Wanigasinghe","year":"2019","unstructured":"Wanigasinghe J, Arambepola C, Murugupillai R, et al. Age, sex and ethnic differentials in the prevalence and control of epilepsy among Sri Lankan children: a population-based study. BMJ Paediatr Open. 2019;3(1):e000430. https:\/\/doi.org\/10.1136\/bmjpo-2018-000430.","journal-title":"BMJ Paediatr Open"},{"key":"4837_CR19","volume-title":"Council for International Organizations of Medical Sciences","author":"World Health Organization","year":"1999","unstructured":"World Health Organization. Council for International Organizations of Medical Sciences. Reporting adverse drug reactions. Geneva: WHO; 1999.\u00a0Available at\u00a0https:\/\/cioms.ch\/wp-content\/uploads\/2017\/07\/Int-Reporting-Adv-Drug-Reactions-1987.pdf. Accessed on Oct 25 2025."},{"issue":"2","key":"4837_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.11622\/smedj.2016022","volume":"58","author":"R Gurumurthy","year":"2017","unstructured":"Gurumurthy R, Chanda K, Sarma G. An evaluation of factors affecting adherence to antiepileptic drugs in patients with epilepsy: a cross-sectional study. Singapore Med J. 2017;58(2):98\u2013102. https:\/\/doi.org\/10.11622\/smedj.2016022.","journal-title":"Singapore Med J"},{"key":"4837_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-0500-6-473","volume":"6","author":"M Habib","year":"2013","unstructured":"Habib M, Khan SU, Hoque MDA, et al. Antiepileptic drug utilization in Bangladesh: experience from Dhaka Medical College Hospital. BMC Res Notes. 2013;6:1\u20138. https:\/\/doi.org\/10.1186\/1756-0500-6-473.","journal-title":"BMC Res Notes"},{"key":"4837_CR22","doi-asserted-by":"publisher","first-page":"8490639","DOI":"10.1155\/2018\/8490639","volume":"2018","author":"A Budikayanti","year":"2018","unstructured":"Budikayanti A, Qadri LM, Syeban Z, et al. Adverse events of antiepileptic drugs using Indonesian version of liverpool adverse events profile. Neurol Res Int. 2018;2018:8490639. https:\/\/doi.org\/10.1155\/2018\/8490639.","journal-title":"Neurol Res Int"},{"key":"4837_CR23","doi-asserted-by":"publisher","first-page":"109383","DOI":"10.1016\/j.yebeh.2023.109383","volume":"146","author":"J Pablo Orozco-Hern\u00e1ndez","year":"2023","unstructured":"Pablo Orozco-Hern\u00e1ndez J, Stiven Mar\u00edn-Medina D, Valencia-V\u00e1squez A, et al. Predictors of adverse effects to antiseizure drugs in adult patients with epilepsy from Colombia: a case\u2013control study. Epilepsy Behav. 2023;146:109383. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109383.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"4837_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2050312118772471","volume":"6","author":"MB Ayalew","year":"2018","unstructured":"Ayalew MB, Muche EA. Patient reported adverse events among epileptic patients taking antiepileptic drugs. SAGE Open Medication. 2018;6(1):1\u20138. https:\/\/doi.org\/10.1177\/2050312118772471.","journal-title":"SAGE Open Medication"},{"key":"4837_CR25","doi-asserted-by":"publisher","first-page":"108841","DOI":"10.1016\/j.yebeh.2022.108841","volume":"134","author":"K Jin","year":"2022","unstructured":"Jin K, Obara T, Hirano K, et al. Prescription trends in anti-seizure medications for adult patients with epilepsy in Japan: a retrospective cohort study using the database of health insurance claims between 2015 and 2019. Epilepsy Behav. 2022;134:108841. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108841.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"4837_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4103\/ijmr.IJMR_710_15","volume":"145","author":"R Joshi","year":"2017","unstructured":"Joshi R, Tripathi M, Gupta P, et al. Adverse effects & drug load of antiepileptic drugs in patients with epilepsy: monotherapy versus polytherapy. Indian J Med Res. 2017;145(3):317\u201326. https:\/\/doi.org\/10.4103\/ijmr.IJMR_710_15.","journal-title":"Indian J Med Res"},{"issue":"5","key":"4837_CR27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJM200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314\u20139. https:\/\/doi.org\/10.1056\/NEJM200002033420503.","journal-title":"N Engl J Med"},{"key":"4837_CR28","doi-asserted-by":"publisher","first-page":"1584566","DOI":"10.3389\/fphar.2025.1584566","volume":"16","author":"M De Bellis","year":"2025","unstructured":"De Bellis M, d\u2019Orsi G, Rubino EM, et al. Adverse effects of antiseizure medications: a review of the impact of pharmacogenetics and drugs interactions in clinical practice. Front Pharmacol. 2025;16:1584566. https:\/\/doi.org\/10.3389\/fphar.2025.1584566.","journal-title":"Front Pharmacol"},{"key":"4837_CR29","doi-asserted-by":"publisher","first-page":"175628642110374","DOI":"10.1177\/17562864211037430","volume":"14","author":"T Hakami","year":"2021","unstructured":"Hakami T. Efficacy and tolerability of antiseizure drugs. Ther Adv Neurol Disord. 2021;14:17562864211037430. https:\/\/doi.org\/10.1177\/17562864211037430.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"4837_CR30","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.4103\/0028-3886.359162","volume":"70","author":"MM Mehndiratta","year":"2022","unstructured":"Mehndiratta MM, Kukkuta Sarma GR, Tripathi M, et al. A Multicenter, Cross-Sectional, Observational Study on Epilepsy and its Management Practices in India. Neurol India. 2022;70(5):2031\u20138. https:\/\/doi.org\/10.4103\/0028-3886.359162.","journal-title":"Neurol India"},{"key":"4837_CR31","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1186\/1471-2458-14-817","volume":"14","author":"PR Dabare","year":"2014","unstructured":"Dabare PR, Wanigatunge CA, Beneragama BH. A national survey on availability, price and affordability of selected essential medicines for non-communicable diseases in Sri Lanka. BMC Public Health. 2014;14:817. https:\/\/doi.org\/10.1186\/1471-2458-14-817.","journal-title":"BMC Public Health"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04837-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04837-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04837-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:36:50Z","timestamp":1777426610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04837-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4837"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04837-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8226066\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles outlined in the Declaration of Helsinki. Ethical approval was obtained from the Ethics Review Committee, Faculty of Medicine, University of Jaffna, Sri Lanka (J\/ERC\/24\/155\/NDR\/0312). Informed written consent was obtained from all participants prior to enrolment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"287"}}